ADMA Biologics Inc $ADMA Shares Sold by Catalio Capital Management LP

Catalio Capital Management LP decreased its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 17.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 564,461 shares of the biotechnology company’s stock after selling 120,047 shares during the quarter. ADMA Biologics accounts for approximately 1.9% of Catalio Capital Management LP’s investment portfolio, making the stock its 22nd largest holding. Catalio Capital Management LP’s holdings in ADMA Biologics were worth $10,296,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rothschild Investment LLC lifted its holdings in shares of ADMA Biologics by 373.8% during the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,495 shares during the period. Clearstead Advisors LLC lifted its holdings in shares of ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 795 shares during the period. iSAM Funds UK Ltd acquired a new stake in shares of ADMA Biologics during the third quarter worth about $34,000. RiverPark Advisors LLC acquired a new stake in shares of ADMA Biologics during the third quarter worth about $35,000. Finally, Optima Capital LLC acquired a new stake in shares of ADMA Biologics during the fourth quarter worth about $36,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Transactions at ADMA Biologics

In related news, Director Jerrold B. Grossman purchased 12,500 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $8.01 per share, with a total value of $100,125.00. Following the completion of the acquisition, the director owned 513,884 shares of the company’s stock, valued at $4,116,210.84. The trade was a 2.49% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on ADMA. Canaccord Genuity Group decreased their target price on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Raymond James Financial began coverage on ADMA Biologics in a report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price for the company. Zacks Research downgraded ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th. Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Finally, Mizuho decreased their target price on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $19.67.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: No meaningful positive company-specific catalysts were announced in the provided news flow.
• Neutral Sentiment: Multiple law firms said investors can seek lead-plaintiff status, with an important deadline of August 10, 2026, but these notices are largely procedural and do not change the underlying allegations. Article Title
• Negative Sentiment: Several class-action lawsuits were filed or publicized against ADMA Biologics, Inc. for alleged securities fraud tied to revenue recognition and internal control issues, creating a significant legal risk overhang. Article Title
• Negative Sentiment: Some allegations specifically reference channel stuffing and an undisclosed related-party distributor, which could raise concerns about the quality of ADMA’s reported sales and controls. Article Title

ADMA Biologics Trading Down 1.9%

Shares of NASDAQ:ADMA opened at $8.42 on Thursday. ADMA Biologics Inc has a 12-month low of $7.21 and a 12-month high of $20.46. The company has a market capitalization of $1.95 billion, a PE ratio of 12.38 and a beta of 0.72. The business has a 50 day moving average of $9.13 and a two-hundred day moving average of $13.90. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The company had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. During the same period in the previous year, the company posted $0.11 earnings per share. ADMA Biologics’s revenue for the quarter was down .3% on a year-over-year basis. As a group, analysts forecast that ADMA Biologics Inc will post 0.82 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.